English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Why Europe Keeps Cracking Down on Ayahuasca — And What It Means for Seekers
A few months back, a Spanish YouTuber spent nine months pretending to be a sincere seeker inside a Santo Daime church. He filmed ceremonies with a hidden camera, edited the footage into something theatrical, and posted it to an audience of hundreds of thousands. The video framed ayahuasca, master plants, and the people who drink them as a brainwashing cult dealing illicit drugs to the vulnerable. Talk-show appearances followed. So did police raids on two unrelated neoshamanic groups. And just like that, public opinion in Spain on one of the world's oldest plant medicines tilted sharply backwards. If you're reading this while weighing whether to book an ayahuasca retreat — in Peru, Costa Rica, Portugal, anywhere — episodes like this matter. Not because they reflect what ceremonies actually are, but because they shape the legal landscape you'll be walking into, the headlines your family will read while you're away, and the broader cultural conversation around psychedelics and addiction recovery. So let's talk about what's actually happening in Europe, why it keeps happening, and what an honest reader should make of it. The short version: one person with a camera, a serious appetite for clicks, and a sensational framing managed to do more damage to the public image of ayahuasca in Spain than a decade of clinical research has been able to repair. He also filed a complaint claiming attempted kidnapping after members of the church confronted him about the secret filming. Whatever the legal merits of that, it gave news producers a juicy hook — and they ran with it. Spanish media has historically struggled with ayahuasca. The scientific literature on the brew — its safety profile in ceremonial settings, its effects on depression and addiction, its centuries-long ritual use — exists, and is mostly ignored when a tabloid story breaks. Instead, the framing defaults to the same tired script: a dangerous sect, a charismatic leader, gullible victims, illegal substances, money changing hands. It's a story shape that sells. It's also, in most cases involving established ayahuasca communities, wrong. The fallout has been real. Raids. Arrests. A chilling effect on groups that have been quietly operating for years without incident. And, importantly for you as a reader, a renewed debate about whether ayahuasca should be legal in Spain at all. Spain isn't an outlier. It's part of a pattern that's been unfolding across Europe for nearly twenty years. France banned ayahuasca and its constituent plants in 2005 — three months after a Santo Daime group in Paris was actually acquitted of trafficking charges. The acquittal should have been a turning point. Instead, the Ministry of Health, with input from MIVILUDES (the French government's cult-monitoring body), pushed through a prohibition. The same Santo Daime leader who was cleared in 2005 was arrested again in 2019 and is still awaiting trial. He could face years in prison. Italy followed suit in March 2022, when the Ministry of Health issued a decree banning ayahuasca, the plants used to brew it, and its active compounds. Italian Santo Daime members were so caught off guard they held ceremonies drinking water instead of the brew — a quiet protest echoing what the União do Vegetal did during their US court fight years earlier. The Netherlands had been the European exception for almost two decades, tolerating religious ayahuasca use after a 2001 court decision. That tolerance ended in 2018, when Dutch courts reversed course and effectively closed the door. Notice what unites these cases. None of them turned on new scientific evidence of harm. None followed a wave of medical emergencies. They followed political and cultural anxieties — about cults, about drugs, about religious minorities doing unfamiliar things in candle-lit rooms. Yes, and the contrast matters. Brazil, where ayahuasca religions like Santo Daime, Barquinha, and União do Vegetal were born in the 1930s through 1960s, has gone the opposite direction. Way back in 1987, a federal Brazilian commission studied the religious use of ayahuasca and concluded there was no evidence of health risk or social harm. Subsequent rulings in 2006 and 2010 formally recognized religious ayahuasca use as constitutionally protected. The country is now in the process of recognizing the brew as intangible cultural heritage — moving it out of drug policy entirely and into the realm of cultural protection. Peru recognized ayahuasca as national cultural heritage to protect traditional and Indigenous use. Colombia has no formal regulation, but Indigenous communities have built self-regulation frameworks, and administrative rulings have legitimized the ceremonial use of yagé. In the United States, two religious groups — the UDV and certain Santo Daime branches — won the legal right to use ayahuasca after Supreme Court and federal court decisions. Costa Rica operates in a gray zone that has, in practice, allowed retreats to flourish. If you're booking an ayahuasca retreat right now, this geography is the reason most reputable centers are in South America. The legal infrastructure that took fifty years to build there is what allows ceremonies to happen openly, with safety protocols, screening, and accountability. The simplest answer is also the most cynical: ayahuasca got popular. Once a brew known mainly to anthropologists and a handful of religious congregations, it now circulates in global wellness conversations, celebrity interviews, podcasts about psychedelic healing, and serious clinical trials for depression and addiction. The psychedelic renaissance has pulled master plants into the mainstream. Whenever something sacred goes mainstream, three things happen at once: You can hold two truths at the same time. Bad actors exist in the plant-medicine world; some retreats are unsafe, some facilitators are predatory, some ceremonies cause harm. AND the response from several European governments has been wildly disproportionate, ignoring decades of evidence about responsible ceremonial use and lumping centuries-old religious traditions in with sketchy weekend retreats. Here's where I'll get practical, because that's probably why you scrolled this far. First, know the law of the country you're traveling to, not just the country you live in. Drinking ayahuasca in Peru is legal and culturally protected. Bringing it home is not. If you live in France, Italy, or Spain right now, your retreat itself isn't the legal risk — what happens at the airport on the way back, if you tried to bring anything home, very much is. Don't. Second, choose retreats with histories you can actually verify. The Santo Daime church being filmed by that YouTuber has decades of documented practice, theological literature, and international branches. That's a different category from someone who learned to pour ayahuasca on a six-month trip and started a center in Tulum. Both might call themselves legitimate. They aren't equivalent. Third, screening matters. Reputable ayahuasca retreats — and reputable centers working with master plants in general, whether that's San Pedro, kambo, or psilocybin — will ask you serious questions before accepting your booking. Medications you take (SSRIs are a real interaction risk). Mental health history. Cardiovascular conditions. If a retreat doesn't ask, that's a red flag the size of a maloca. Fourth, think hard about why you want to go. Plant medicine has shown real promise for addiction, depression, PTSD, and the kind of stuck life patterns that talk therapy alone often can't shift. It's also not a magic eraser. The people I've watched get the most out of ceremony work tend to share two qualities: they came in with a specific question or wound, and they took integration seriously afterwards. The ones who treated it like an extreme sport mostly got an extreme experience and not much else. The European crackdowns are real, and they're not going away tomorrow. But they're also not the whole story. Indigenous federations in Brazil have been organizing conferences since 2017 to defend their ancestral use of ayahuasca. Researchers across multiple countries are publishing on its therapeutic potential. Clinical trials for psilocybin and MDMA are quietly normalizing the broader conversation about psychedelic healing. The cultural pendulum, despite the headlines, is still moving — just unevenly. For someone deciding whether to drink ayahuasca, the takeaway isn't really about politics. It's about doing your homework: pick a country where the practice is protected, pick a center with a track record, prepare your body and mind seriously, and treat the days after the ceremony as more important than the ceremony itself. If something here speaks to you, the available ayahuasca retreats and broader plant-medicine ceremonies can be browsed and booked on our marketplace here. Take your time with the choice. The plant has been around for centuries. It can wait a few more weeks while you find the right place.
The Science of Psilocybin Therapy: What Mushrooms Actually Do to the Brain
Here's something most people don't realize when they first start reading about psychedelic healing: the mushrooms aren't doing the heavy lifting. The mushrooms crack the door. What walks through it — old grief, buried memory, the version of yourself you've been avoiding for fifteen years — that's the actual work. And the science of psilocybin therapy is finally catching up to what curanderos and underground therapists have quietly known for decades. If you're researching a psilocybin retreat, or wondering whether psychedelics could help with the depression or addiction or stuck pattern that hasn't budged with anything else, you deserve a real answer rather than a glossy one. So let's get into what the research actually shows, what happens in the brain, and what an honest decision-making process looks like before you commit your money and your nervous system to a journey. Psychedelic therapy, at its simplest, is the supervised use of substances like psilocybin, MDMA, LSD, or ketamine in combination with psychotherapy. The substance creates an altered state. The therapist — or a trained facilitator, depending on the setting — helps the person prepare for that state, holds space during it, and then guides the integration afterward. The integration piece is the part people skip in articles, and it's also the part that determines whether you come home changed or just come home with a story. Two broad models tend to show up. The first is psycholytic therapy, which uses smaller, more frequent doses over many sessions. The person stays largely lucid and the therapist works conversationally. The second, and the one most modern clinical trials are built around, is high-dose therapy — one to three big sessions, eyeshades on, curated music in the headphones, minimal talking. The facilitator's job is mostly to keep you safe so your own psyche can do what it needs to do. What makes this approach different from standard psychiatry is the durability of the results. Three sessions. Sometimes one. That's not how SSRIs work. That's not how years of weekly talk therapy work. Something else is happening here, and researchers are finally allowed to ask what. For decades, the research was effectively frozen. After the cultural collision of the late 1960s, psilocybin landed on Schedule I in the United States and the labs went dark. The last few years have changed that. Institutions like Johns Hopkins and Imperial College London have been quietly producing studies that read less like cautious science and more like a slow-motion paradigm shift. The headline findings cluster around a few areas — treatment-resistant depression, end-of-life anxiety, addiction (especially nicotine and alcohol), obsessive-compulsive disorder, and PTSD. The effect sizes in these trials are, to put it plainly, unusual. We're not talking about a 10% improvement over placebo. We're talking about studies where the majority of participants experience meaningful, sustained change after a small number of sessions. A 2016 Johns Hopkins study gave psilocybin to patients with life-threatening cancer who were struggling with depression and existential dread. Roughly 80% reported a significant reduction in both depression and anxiety, and the effect held for at least six months. Many described what they'd seen as the most personally meaningful experience of their lives — ranked alongside the birth of a child or the death of a parent. That's not a sentence you read in clinical literature very often. A smaller 2014 Johns Hopkins study looked at psilocybin paired with cognitive behavioral therapy for people trying to quit smoking. Fifteen participants. Two or three high-dose sessions. At the twelve-month follow-up, 67% were still cigarette-free. For context, the best pharmaceutical smoking-cessation drugs hover around 35% at six months and drop from there. The number isn't a fluke — it's been replicated in extended follow-ups — and it suggests something important about how psilocybin works on addiction at a level deeper than nicotine cravings. When researchers at Imperial College London first put people on psilocybin into fMRI scanners, they expected to see the brain light up. Psychedelic, more activity — seemed obvious. The opposite happened. Activity in a region called the default mode network actually went down. The default mode network is the brain's autopilot. It's the chatter that runs when you're not focused on a task — the planning, the worrying, the rehearsing of conversations you'll never have. It's also where most neuroscientists think the sense of self, the ego, gets constructed. When psilocybin quiets it, the result is what people across cultures have been describing for thousands of years: ego dissolution, the sense that the boundary between self and everything else has gone soft. That softening is the therapeutic mechanism. With the ego less in charge, material that's been locked away — trauma, grief, shame, the story you tell yourself about who you are — can surface and be reconsidered. The brain also forms unusual new connections during the experience, with regions that don't normally talk to each other suddenly in conversation. Some researchers describe it as the snow globe of your psyche being shaken so the patterns can settle differently. Psilocybin isn't operating alone in this field. Several other substances — many of them traditional master plants used by indigenous cultures for centuries — are showing similar therapeutic promise. Each of these works differently. Each carries its own risks, its own ceremonial lineage (or lack of one), and its own integration demands. Treating them as interchangeable is one of the more common mistakes people make when they're new to this space. Psilocybin remains illegal in most jurisdictions, though that's shifting. Oregon and Colorado have established legal therapeutic frameworks. Retreats operate legally in the Netherlands (where truffles containing psilocybin are permitted), Jamaica, and parts of Mexico. Clinical trials exist for those who qualify and can wait. Before you book anything, the questions worth sitting with: Public opinion on psychedelics has shifted faster in the past five years than in the previous fifty. Michael Pollan's writing brought the conversation into living rooms it had never reached before. The FDA has granted breakthrough therapy designation to psilocybin for treatment-resistant depression. Clinical trials are expanding into Alzheimer's, anorexia, chronic pain, and grief. None of that means psychedelic therapy is a solved problem. It isn't. There are people for whom these substances are genuinely contraindicated — anyone with a personal or family history of psychosis or bipolar disorder, for starters. There are bad trips that aren't transformative, just bad. There are retreats that take your money and send you home raw with nothing to land on. And there's a quiet phenomenon researchers are starting to name: the spiritual bypass, where people use big experiences to skip over the unglamorous, daily work of actually changing their lives. Still, what's emerging from the labs and the long-running ceremonial traditions is pointing in the same direction. Used carefully, in the right setting, with real preparation and real integration, these medicines can move things that nothing else moves. For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly — the mushrooms have been around for a few million years and will wait.
From Wall Street to the Maloca: How One Man Built a Psychedelic Concierge Service for the Stars
There's a particular kind of person who shows up to an ayahuasca retreat in their late forties carrying a duffel bag and a quiet panic. They've done the things. Built the company, raised the kids, hit the income bracket. And somewhere around the second night of ceremony, sitting cross-legged in a thatched-roof maloca somewhere in the Sacred Valley, they realize they've been chasing the wrong thing for twenty years. I've sat with a few of them. The story I want to tell you here is one of the louder versions of that script — a former investment banker who flipped his life sideways after his first cup of ayahuasca and now spends his days connecting celebrities, veterans, and curious millionaires with the plant medicines and psychedelic compounds he thinks they need. It's a useful story, even if you have zero interest in being a celebrity, because it surfaces almost every question a serious person should be asking before booking a psychedelic retreat. The short version: a guy made a small fortune in the dot-com era buying and flipping premium domain names — the kind of generic single-word URLs that became digital real estate when the internet was still figuring itself out. By any external measure, he'd won. Big house, full bank account, the works. Then around 2011, he hit what he calls a spiritual midlife crisis. The familiar one. He'd done everything the culture promised would deliver fulfillment, and the fulfillment hadn't shown up. So he flew to Peru, sat with a shaman, drank ayahuasca, and — like a lot of people in that chair — came home rearranged. That's the part of the story that interests me most, because it's not unique. I've heard versions of it from tech founders, ER doctors, divorced dads, recovering addicts, and one extremely tired oncology nurse. The plant doesn't care about your portfolio. It hands everyone the same mirror. After his first ceremony, this entrepreneur started introducing friends to plant medicine. Word spread. Actress wants to try ayahuasca? He'd organize the trip. Retired NBA player struggling with addiction? He'd recommend ibogaine in Mexico, where it's legally accessible, then a ketamine clinic back in Florida for integration. The role evolved into something he describes as a concierge — except instead of asking what kind of cuisine you're into, he's asking what kind of trauma you're carrying. Here's the thing the celebrity framing tends to obscure: this is essentially the same triage that any honest plant-medicine practitioner does with a new participant. What are you actually here for? What have you tried? What's the intent? The answers shape the recommendation — ayahuasca for the long, mythic, sometimes brutal night journey. Psilocybin for emotional softening. Ibogaine for the addiction-interrupt some research suggests it can produce. Ketamine for clinical depression that hasn't budged with anything else. Most readers reading this won't have a concierge. You'll be sifting retreat websites at midnight, comparing prices, trying to figure out whether the operation in Iquitos is legit or a tourist trap with a guy in feathers. But the framework applies anyway: start with intent, work backwards to the medicine. Let me walk through the main players in this story, because they keep getting lumped together as "psychedelics" when they're genuinely different tools. These tools overlap, but they're not interchangeable. Choosing the wrong one for the wrong reason is one of the more common mistakes I see in first-timers. This is one of the most-searched questions in the space, and it deserves a careful answer. The case for ibogaine and addiction is the strongest of the bunch. Studies and clinical observations from clinics in Mexico, Costa Rica, and elsewhere suggest a single ibogaine session can interrupt the physical dependency of opioid addiction and produce what users describe as a long, autobiographical "life review" that recontextualizes the addiction itself. It's not a cure. People do relapse. But for some, it's the first crack in a wall they've been throwing themselves at for years. Ayahuasca and psilocybin have softer evidence for addiction but stronger evidence for the underlying conditions that often drive it — depression, PTSD, chronic shame, unresolved trauma. The thinking in the field is that you're not really treating the addiction; you're treating the reason the person started self-medicating in the first place. Both can be true. People who do plant medicine work alongside therapy and a recovery community tend to fare better than those who treat the ceremony as a one-shot fix. If you or someone close to you is weighing this for serious addiction, please don't go it alone. The integration matters as much as the ceremony. Probably more. Most of the substances above remain federally illegal in the United States. That hasn't stopped a wave of legal change at the edges — Oregon's psilocybin services framework, decriminalization in cities like Denver, Oakland, and Detroit, and the slow march of FDA-approved trials for MDMA and psilocybin. In the meantime, what people actually do is travel. Peru, Costa Rica, the Netherlands (for psilocybin truffles), Mexico (for ibogaine and bufo), Jamaica (for psilocybin) — these are the destinations where the medicines are either legal, regulated, or operating in tolerated grey zones. A reputable retreat will be transparent about its legal standing. A sketchy one will dodge the question or insist you not photograph the property. Ketamine occupies its own category in the U.S. — it's a legal anesthetic, and clinics offering it off-label for depression have multiplied. At-home ketamine telemedicine has also exploded, with mixed quality. Some operations do real intake screening and pair the medicine with therapy. Others mail lozenges to anyone with a credit card and a vague symptom list. Buyer beware. If this article has nudged you closer to booking something, a few things I'd want a friend to know before they put down a deposit: What strikes me about the concierge story is how thoroughly it mirrors a cultural shift that's been building for a decade. Plant medicine and psychedelic healing have moved from countercultural fringe to wellness mainstream — sometimes too quickly, sometimes with too much hype, but moved nonetheless. Veterans with PTSD are using ketamine. Tech founders are microdosing psilocybin. A documentary about an actress drinking ayahuasca won an award at a Dutch film festival a few years back. The taboo is thinning. What hasn't changed is the part the headlines tend to skip: this work is genuinely hard. The ceremony itself is one night. The integration — the slow, unflashy practice of changing how you live based on what you saw — is the rest of your life. Anyone selling you the first without preparing you for the second is selling you a souvenir. If something in this piece resonated and you want to look at what's actually out there, a curated selection of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicines aren't going anywhere, and the readiness usually arrives when it arrives — not a moment sooner.
What Drinking Ayahuasca Actually Feels Like: An Honest Account
Ask anyone who's actually done it, and you'll get the same long pause before they answer. Drinking ayahuasca isn't something you summarize at a dinner party. The brew has been making its way out of the Amazon and into Western conversation for decades now, but the gap between what people imagine and what actually happens in ceremony is enormous. If you're reading this because you're weighing whether to fly to Peru, Costa Rica, or somewhere closer to home for a retreat, you deserve a straight account — not a sales pitch and not a fever dream. So let's talk about it plainly. What does ayahuasca taste like? What does it do to your body? What does it do to your mind? And what, honestly, is the point — especially if you're someone quietly hoping a plant medicine might help with addiction, depression, or a pattern in your life that won't budge? Ayahuasca is a brew. That sounds obvious, but it's worth saying because a lot of newcomers picture a pill or a powder. It's a dark, syrupy liquid, traditionally simmered for hours — sometimes a full day — over a wood fire in the Amazon. The two main ingredients are the Banisteriopsis caapi vine (the ayahuasca vine itself) and the leaves of the chacruna shrub, though some traditions use other admixture plants. The vine contains MAO inhibitors. The chacruna contains DMT. Neither does much on its own when taken orally — your stomach would shut the DMT down before it ever reached your brain. Together, though, they unlock something that indigenous peoples of the Amazon basin figured out long before any chemistry textbook explained why it works. That's part of what makes the brew remarkable. It's a piece of pharmacology that emerged from a rainforest with tens of thousands of plant species, somehow combined in exactly the right way. Across the upper Amazon — Peru, Colombia, Ecuador, Brazil — ayahuasca is woven into healing traditions that go back generations. It's considered one of the master plants: teacher plants believed to carry intelligence, to instruct the people who drink them. You don't have to subscribe to that worldview to take it seriously. Plenty of skeptical, secular people walk into a ceremony and come out describing things they can't explain. Here's the part nobody glamorizes. It tastes terrible. Picture earth, bark, bile, and stewed coffee grounds, all warmed up. Some people compare it to swamp water. Others say burnt molasses. The point is: you don't sip ayahuasca for the flavor. You drink the cup the facilitator hands you, you set it down, and you wait. The first twenty to forty minutes are quiet. Maybe you feel a slight buzz, a heaviness in your limbs, a shift in how sounds register. Then the icaros — the sung medicine songs — begin, and somewhere underneath them, the brew starts working. People describe it differently: The purging — vomiting, sometimes diarrhea — is part of it. Western readers tend to flinch at this. In the Amazonian tradition, it's not a side effect. It's the medicine doing what it came to do, clearing what it considers ready to leave. Almost every retreat hands you a personal bucket. You'll use it. So will the person next to you. The choreography of a ceremony includes a fair amount of quiet retching, and somehow it becomes ordinary within about twenty minutes. This is the part that's hardest to describe, because language is built for ordinary experience and ayahuasca isn't ordinary. Some people see visions — jaguars, snakes, lattices of color, vast architectures of light. Others don't see much at all and instead are walked through their own memories with a clarity that's almost unbearable. A childhood scene you hadn't thought about in thirty years suddenly arrives in HD, and you understand something about it you'd never understood before. The recurring theme in honest accounts isn't fireworks. It's confrontation. Ayahuasca tends to show people what they've been avoiding. The drinker who came in hoping for cosmic union with the universe might instead spend six hours examining how they've been treating their partner. The person who came for relief from depression might be shown the specific moment, decades back, where the depression set up shop. It can be brutal. It can also be tender — many people report being held, comforted, taught. There's an old joke in this world: ayahuasca gives you what you need, not what you want. Funny because true. This is the question I get most often, and it deserves a careful answer. The short version: there is real, growing evidence that ayahuasca and other psychedelics can support addiction recovery — but it's not a magic eraser, and the people who do best treat the ceremony as the beginning of work, not the end of it. Studies out of Brazil, Canada, and Spain have followed people who used ayahuasca in ceremonial contexts and tracked reductions in problem drinking, cocaine use, and tobacco dependence. Clinical trials with psilocybin for alcohol use disorder have shown encouraging results. Ibogaine, another plant-derived psychedelic from West Africa, has decades of underground use treating opioid addiction, with some clinics now operating legally in Mexico and Costa Rica. What seems to happen, across these substances, is twofold. First, there's a neurological reset — the brain becomes briefly plastic, old patterns loosen, new connections form. Second, and arguably more important, people see their addiction differently. They see what it cost them. They see what they were medicating. They see a version of themselves not yoked to the substance, and they remember that version exists. Whether that change holds depends on what they do in the months that follow. None of this is a substitute for medical care if you're in a serious addiction situation. Ayahuasca interacts badly with SSRIs, MAOIs, and certain heart and blood pressure medications. People with personal or family histories of psychosis or bipolar disorder are generally screened out by responsible retreats. If you're considering plant medicine for addiction, talk to a doctor who won't dismiss the conversation, and choose a retreat with real medical screening, not a questionnaire someone glances at over email. The plant-medicine world has matured, but it's still uneven. For every excellent center run by experienced facilitators and indigenous-trained shamans, there's a glossy website hiding a sketchy operation. Here's what experienced retreat-goers actually look for: Trust your gut on this one. If a retreat's marketing feels more like a wellness brand than a serious medicine container, keep looking. The dieta — the period of dietary and lifestyle restriction before ceremony — isn't optional. Most retreats ask you to cut alcohol, recreational drugs, red meat, pork, fermented foods, processed sugar, and sexual activity for one to two weeks before arrival. Some include cilantro, aged cheese, and a long list of medications. This isn't religious theater. The MAO inhibitors in the vine genuinely interact with tyramine-rich foods and many pharmaceuticals, and the dieta is partly a safety measure. It's also psychological preparation. By the time you arrive, you've already changed your habits. You've already noticed how much you reach for wine at night, or sugar after lunch, or scrolling at 11pm. The brew hasn't started yet and you're already learning. Afterward — and this matters more than the ceremony itself, in my opinion — comes integration. The week or month after a strong ayahuasca experience can feel raw, lit up, sometimes destabilizing. People reconsider jobs, relationships, where they live. Some of these reconsiderations are wise. Some are the medicine talking before it has fully settled. Good practice is to wait a month or two before making any irreversible decision, and to work with an integration therapist or sober friend who can help you sort signal from noise. Honest answer: maybe. Ayahuasca isn't for everyone, and the romanticization of it has done some real damage. People with certain medical conditions shouldn't drink it. People in active crisis often need stabilization before any psychedelic work. People looking for a quick fix tend to come back disappointed — or worse, more lost than they started. But for someone genuinely curious, willing to do the preparation, willing to do the integration, and clear-eyed about the risks — yes, an ayahuasca retreat can be one of the more meaningful weeks of your life. Many people come home with a softer relationship to their own pain, a clearer sense of what matters, and, sometimes, real changes in patterns they'd written off as permanent. Plant medicine isn't a religion, and it isn't a pharmaceutical, and it doesn't need to be either to be worth taking seriously. If you've read this far and something in you is still leaning toward the door marked maybe, take that seriously too. A range of carefully vetted ayahuasca retreats can be browsed on our marketplace here — useful for comparing locations, lineages, and what each container actually offers before you commit. Whatever you decide, decide slowly. The vine has been here for a very long time. It'll wait.
Ibogaine for Opioid Addiction: Could Plant Medicine Crack the Crisis?
The opioid epidemic has outlasted every easy solution thrown at it. Tighter prescribing rules. Naloxone in every paramedic's bag. Methadone clinics. Suboxone scripts. Sober houses. Each one helps somebody — and yet the obituaries keep coming, in rural Ohio, in coastal Maine, in the gated suburbs nobody expected. Somewhere in the middle of that long, exhausting failure, a strange word started showing up in recovery forums and harm-reduction circles: ibogaine. If you've found your way to this article, you probably already know the basics. Ibogaine is a psychoactive compound from the root bark of an African shrub called Tabernanthe iboga. People who've taken it for opioid dependence describe waking up the next day without withdrawal — not white-knuckled, not dope-sick, just… not craving. That's the claim that won't go away. And it's the claim that has Western medicine, very slowly and very awkwardly, starting to pay attention. Let's talk about what ibogaine actually is, what the evidence looks like, what the risks are, and what a person seriously considering a retreat should think through before they book a flight. Iboga has been used ceremonially for centuries by the Bwiti tradition in Gabon and surrounding regions of Central Africa. In that context, it isn't a quick detox tool — it's a rite of passage, a way of meeting the ancestors, of seeing oneself clearly. Doses are large. The experiences last a day or more. People emerge changed, not just chemically but in how they understand who they are. What Western researchers eventually isolated from the bark is an indole alkaloid called ibogaine. Pharmacologically it's a strange creature — it touches opioid receptors, serotonin receptors, NMDA receptors, sigma receptors, and nicotinic receptors all at once. There isn't a single clean mechanism that explains what it does. That polypharmacology is probably part of why it works on addiction at all, and also part of why it carries real cardiac risk. Among the master plants — that loose category of teacher plants like ayahuasca, peyote, and San Pedro — iboga has a particular reputation. People who've sat with several of them often describe iboga as the strictest. Less visionary, more confrontational. A friend who's done both ayahuasca and ibogaine put it bluntly: “Ayahuasca shows you who you could be. Iboga shows you exactly who you are, and doesn't let you look away.” Howard Lotsof, an American who tried ibogaine recreationally in the 1960s while struggling with heroin dependence, noticed something he couldn't explain: his withdrawal symptoms vanished, and his cravings stayed gone for months. He spent decades trying to get medicine to take that observation seriously. Mostly it didn't. But the underground kept the work alive. What the underground figured out, and what a handful of clinical observations have since supported, is that a single high-dose ibogaine session can interrupt opioid dependence in a way that no other pharmaceutical does. Patients walk out of the experience without the weeks of misery that usually accompany kicking opioids. Many describe a long, dreamlike review of their own life — childhood scenes, decisions, regrets, the moments that set the addiction in motion — playing out in front of them while they lie still on a mattress. This is the part that's hard to talk about clinically. The pharmacological reset matters, but the psychological reckoning seems to matter just as much. Ibogaine doesn't feel like recreation. People don't generally want to do it again right away. It's exhausting. And that, paradoxically, is part of what makes it useful for addiction — it doesn't replicate the reward loop that opioids exploit. The honest answer: less than we'd like, and more than skeptics admit. Most of the data on ibogaine comes from observational studies of treatment clinics in Mexico, New Zealand, and a few other jurisdictions where it operates legally or in regulatory gray zones. These studies aren't the gold-standard double-blind trials you'd want — you can't really blind someone to a substance that produces a 24-hour visionary experience — but they're not nothing. What they consistently show: Formal clinical trials are finally beginning to happen. A 2024 Stanford study of ibogaine in military veterans with traumatic brain injury and PTSD produced striking results — significant reductions in PTSD, depression, and anxiety scores that held at follow-up. That study wasn't about opioid addiction specifically, but it broke open the conversation in mainstream medicine in a way two decades of advocacy hadn't. Here's where I have to slow down, because the romance of psychedelic healing tends to gloss over the part that matters most: ibogaine can kill you. Not metaphorically. Cardiac arrhythmia — specifically QT-interval prolongation that can lead to fatal heart rhythms — has caused deaths in ibogaine sessions, including in clinical settings. The deaths are not random. They cluster around predictable risk factors: undiagnosed heart conditions, electrolyte imbalances, interactions with other drugs (including methadone, which has its own QT effects), and clinics that don't do proper medical screening. A responsible ibogaine provider runs an EKG before treatment. They check liver function. They take a careful medication and substance history. They have a cardiologist available or on-call. They use continuous cardiac monitoring during the session. If a provider isn't doing those things, walk away. I don't care how spiritually authentic they sound. I don't care what testimonials they have on their site. The cardiac risk is real and screenable, and any program that treats it casually is a program that will eventually kill somebody. If you're seriously researching this, you should know what a well-run program looks like so you can recognize one when you see it. The pattern across reputable clinics is broadly similar: Costs vary widely. A medically supervised ibogaine program for opioid dependence typically runs between $6,000 and $15,000 USD, depending on country, length of stay, and the level of medical infrastructure. Cheaper than that, you should be asking hard questions about what's being cut. I won't pretend to answer that — nobody on the internet can. But here are the questions I'd want someone in this position to sit with honestly: Ibogaine isn't a magic bullet. It's a powerful interruption — a window. What you build inside that window is the actual recovery. The people I've spoken with who got the most out of it treated the session as the start of the work, not the end of it. The opioid crisis hasn't gone away, and the conventional toolkit, while genuinely lifesaving, isn't enough for everyone. Ibogaine is one of the more promising tools the underground kept alive while the mainstream looked the other way, and it's finally getting the serious research it deserves. For readers who want to take this further, a range of carefully vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Go slowly, ask hard questions, and trust the providers who welcome them.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Ibogaine for Addiction Recovery: What the First Month After Treatment Really Feels Like
People keep asking me what the first month after ibogaine is actually like. Not the ceremony. Not the visions. The part nobody films — the slow weeks afterward when you're back in your apartment with the same fridge and the same phone and the same brain trying to figure out who you are now. That's the part that decides whether the medicine worked. Ibogaine has a strange reputation in the plant medicine and psychedelics world. It doesn't promise bliss. It doesn't sell you a sunset on Instagram. What it does — and what a growing pile of clinical research keeps confirming — is interrupt opioid dependence with a force that nothing else in the pharmacy can match. For people stuck in addiction, that interruption can feel like the first quiet room they've stood in for years. But quiet rooms are not the same as healing, and the month after is where that distinction gets brutal. The short version: the physical withdrawal piece is mostly gone. The cravings, for many people, drop to a whisper. The honeymoon window — what underground providers sometimes call the “grey period” — usually lasts somewhere between three and six weeks. During that stretch, the dopamine system is essentially reset, and the obsessive pull of the substance feels muted in a way that's almost disorienting. The longer version is messier. You sleep badly for the first ten days or so. Your appetite swings. You feel emotionally raw in a way that has nothing to do with the drug you stopped using and everything to do with the feelings you used the drug to avoid. Old memories surface uninvited. Conversations with people you haven't thought about in a decade replay themselves at 3 a.m. The medicine doesn't hand you a clean slate — it hands you the unedited footage and says good luck. What surprises most people is how physically tired they remain. Ibogaine is hard on the body. Heart rhythm, electrolytes, liver — these are not small things, which is why any reputable clinic screens you with an EKG and bloodwork before they'll touch you. Recovery from the session itself can take two to three weeks. You're not bouncing back into the gym on day five. Yes, cravings come back. Not always, not for everyone, but if you're going into this thinking ibogaine is a one-and-done cure, please recalibrate before you spend the money. What it gives you is a window. A real one. Inside that window, the compulsion that ran your life is dialed down enough that you can finally do the work — the therapy, the lifestyle rebuild, the friend group surgery, the boring daily structure — that long-term recovery actually requires. People who use the window well tend to stay clean. People who treat the trip as the finish line tend to relapse, sometimes within two months, sometimes within two weeks. This is one of the most consistent patterns in the underground and clinical data both. That's also why the better clinics insist on aftercare. Some build in booster sessions of iboga (the milder, plant-form cousin) at the 30- or 60-day mark. Some pair you with an integration coach. Some send you home with a structured plan covering sleep, nutrition, movement, meetings, and therapy. If a provider is happy to dose you and wave goodbye, that's a red flag the size of a billboard. I get asked constantly how ibogaine compares to ayahuasca or psilocybin for addiction recovery. Honest answer: they do different jobs. If you're physically dependent on opioids right now, ibogaine is probably the conversation to be having. If you've been clean for a year and you're trying to understand why you got there in the first place, ayahuasca or psilocybin may be the better match. People sometimes do both, in sequence, with months of integration between them. There's no universal map. Integration is the unsexy word for the work that turns a psychedelic experience into a changed life. After ibogaine, it tends to look something like this: Most relapses I've seen happen because someone skipped step three. The medicine bought them a clean runway and they used it to coast instead of to build. Ibogaine has killed people. Not many, but enough that you need to take the screening seriously. The deaths almost always involve undetected heart conditions, dangerous drug interactions (methadone is a particular issue — most clinics require a switch to short-acting opioids weeks in advance), or facilities that lack proper medical monitoring. A legitimate provider will require: a recent EKG, a full blood panel, a detailed medical history, a psychiatric screening, and ideally an in-person medical team during the session itself. They will not take cash from someone who walked in off the street that morning. If anything in that list is missing from the clinic you're considering, walk away. The savings are not worth your life, and the cheap options in this space are cheap for grim reasons. It's also worth saying out loud that ibogaine is not legal in the United States. The retreats people travel to are typically in Mexico, Costa Rica, the Netherlands, or other jurisdictions where the legal status is permissive or grey. Plan accordingly — passport, insurance, someone at home who knows where you are and when to expect contact. For the right person, in the right circumstances, with the right preparation and aftercare — yes, often dramatically so. I've talked to people whose lives genuinely turned a corner after ibogaine. I've also talked to people who spent twelve thousand dollars and were using again by spring. The difference between those two outcomes is rarely about the medicine. It's about everything that surrounded it. If you're considering this seriously, give yourself at least three months of research and preparation before booking anything. Talk to people who've done it. Read the underground forums with a critical eye — the loudest voices are usually either evangelists or skeptics, and the truth tends to live in the quieter middle. For readers who want to compare reputable options side by side, a curated selection of ibogaine and broader plant-medicine retreats can be explored on our marketplace here. Whatever you decide, decide it with your eyes open — the window ibogaine offers is real, and it's also temporary, and what you do with it is the whole game.
How to Store Magic Mushrooms and Truffles So They Stay Potent
So you’ve got a stash of magic mushrooms or truffles sitting on the counter, and the question creeps in: how long will these things actually last? It’s a fair worry. Psilocybin is a delicate molecule, and the way you treat your mushrooms in the days and weeks after you get them holds them is the difference between a meaningful experience later on and a damp bag of disappointment. Whether you’re saving them for a planned ceremony, a microdosing protocol, or just want a small reserve in the cupboard, storage matters more than most people realise. This is a quick, no-nonsense walk through how to keep psilocybin mushrooms and truffles in good shape — what works, what wrecks them, and how long you can realistically expect them to stay potent. None of it is complicated. But the small details make a real difference. Psilocybin and its cousin psilocin are the two compounds doing the heavy lifting in any psychedelic mushroom or truffle. Both are organic molecules, and like most organic molecules they degrade over time — slowly when conditions are right, alarmingly fast when they aren’t. Heat, light, oxygen, and moisture are the four enemies. Hand a fresh truffle all four at once and it’ll be mush within days. The goal of good storage is simple: slow the degradation as much as possible. You can’t stop it entirely. Even perfectly stored dried mushrooms lose a little potency every month. But the gap between “stored well” and “stored badly” is enormous. We’re talking the difference between mushrooms that still hit reliably a year later and mushrooms that taste like wet cardboard and barely register after a fortnight. Fresh psilocybin mushrooms and truffles are mostly water — somewhere around 90% by weight, sometimes more. That moisture is exactly what makes them so fragile. Bacteria love it. Mould loves it. Enzymes inside the mushroom itself happily keep breaking things down even after harvest. If you’re planning to use them within a week or two, the fridge is your friend. Keep them in their original packaging if it’s vacuum-sealed, or transfer them to a paper bag inside a sealed container. Paper absorbs excess moisture; pure plastic traps it and invites rot. Aim for the main body of the fridge rather than the door, where temperatures swing every time someone reaches for the milk. Realistic shelf life for fresh truffles in the fridge: about a month if they were sealed properly at the source, maybe two to three weeks once opened. Fresh mushrooms are even shorter — a week, perhaps two if you’re lucky. Check them regularly. If you see fuzzy white or green spots that aren’t the mushroom’s natural mycelium, or if anything smells sour or ammoniated, throw them out. Psychedelic curiosity is not worth a hospital trip for food poisoning. If you want mushrooms or truffles to last longer than a few weeks, drying is non-negotiable. Properly dried psilocybin mushrooms can hold most of their potency for a year or more in good conditions. Some experienced users report usable potency at two or three years, though there’s a steady downward slope. The trick is to dry them properly — to what people in the cultivation world call “cracker dry.” That means the stems snap cleanly when bent rather than folding. Anything softer, anything that bends like leather, still has too much moisture and will eventually mould. A few methods work well: Avoid the oven. People try it; people regret it. Most home ovens run far too hot at their lowest setting and you’ll cook off a meaningful chunk of the active compounds before you realise. Once they’re cracker dry, the storage rules become straightforward. You want darkness, cool temperatures, low humidity, and minimal exposure to oxygen. An airtight glass jar in a dark cupboard is the classic answer and still one of the best. For longer storage, you can level up: What about light? Direct sunlight is the fastest way to wreck psilocybin. UV rays break the molecule apart with brutal efficiency. Even a bright kitchen shelf is asking for trouble over months. Dark cupboard, drawer, or opaque container — pick one and stick to it. Magic truffles, the underground sclerotia of certain psilocybe species, behave a bit differently from above-ground mushrooms. They’re denser, hold moisture more stubbornly, and are harder to dry evenly without specialist equipment. Most people using truffles consume them fresh from a sealed package within the printed shelf life — usually a couple of months refrigerated, unopened. You can dry truffles, and they’ll keep similarly to dried mushrooms once you do, but the process is slower and you need to slice them thinly to get even drying. If you’re not set up for this, sticking with fresh truffles and using them within their fridge window is the simpler route. Your senses are reliable here. Healthy dried mushrooms smell faintly earthy and almost like old hay. Anything sharp, sour, ammonia-like, or actively unpleasant means something has gone wrong — usually moisture creeping in and feeding bacteria or mould. Visible mould in any colour is a hard stop. So is a slimy or sticky texture in something that should be brittle. Loss of potency is harder to spot visually. Mushrooms that have slowly degraded over a couple of years often look fine but simply don’t hit the way they used to. If you’re returning to an old stash, start with a smaller dose than you remember being effective and see where you land. This applies double if you’re using mushrooms for any kind of intentional inner work — not knowing your dose is one of the easiest ways to turn a meaningful evening into an unnecessarily rough one. Psilocybin remains a controlled substance in many countries, and the legal status of mushrooms, truffles, spores, and grow kits varies wildly depending on where you live. Storage advice is technical, not legal — please look up your own jurisdiction before assuming anything. And while keeping your stash fresh is useful, it’s worth asking why you’re storing it in the first place. Mushrooms aren’t snacks. If you’re sitting on a meaningful supply with no clear plan for using it, that’s often a sign that working with a facilitator or a structured retreat setting would serve you better than another solo trip in the living room. People who use psychedelics most productively tend to do so with intention, support, and integration — not because they happened to have some in the cupboard. For readers who feel ready to take the experience deeper than what a home stash can offer, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, store what you have well — fresh, dark, cool, and dry — and treat it with the respect any real medicine deserves.
The History of Psychedelics: From Cave Paintings to Plant Medicine Retreats
The history of psychedelics is older than most religions, older than written language, and — depending on which cave painting you trust — possibly older than agriculture itself. That matters. If you're reading this because you're weighing a ceremony or a retreat, it helps to know that ayahuasca, peyote, psilocybin, and the rest aren't a wellness trend invented last Tuesday. They're part of a long, messy, beautifully human story about people trying to understand consciousness, heal sickness, and reckon with what some traditions call the master plants. This is a tour through that story. We'll move from prehistoric murals to Spanish conquistadors, from a Swiss chemist's bicycle ride to the modern psychedelic research labs at Johns Hopkins. Along the way, I'll point out where the trail goes cold, where the science gets interesting, and what it all means for someone considering plant medicine for addiction, depression, or the slower kind of stuck that doesn't have a name yet. The deepest archaeological trail leads to a cave in the Tassili-N-Ajjer plateau in the Algerian Sahara. Painted on its rock walls, somewhere between 7,000 and 9,000 years old, is a figure researchers nicknamed the “mushroom shaman” — a bee-headed character with mushrooms growing out of his body. Scholars believe the species depicted is Psilocybe mairei, a psychedelic mushroom native to North Africa. Take a moment with that. People were painting their visions on cave walls before anyone built a pyramid. Across the Atlantic, the evidence is just as old. In the Rio Grande region of what's now Texas, peyote specimens dating back to roughly 3,700 BC have been analysed for mescaline content. The conclusion was straightforward: Indigenous North Americans recognised the psychoactive properties of peyote at least 5,700 years ago. In northern Peru, a stone carving from around 1,300 BC shows a deity clutching a San Pedro cactus — another mescaline-bearing plant still used in ceremony today. Further south, in Mexico and Guatemala, archaeologists have unearthed carved “mushroom stones” dated between 1,000 and 1,500 BC, widely interpreted as ritual objects connected to psilocybin use. And in 2019, researchers described a 1,000-year-old shaman's pouch found in southwestern Bolivia, containing snuffing tablets, a snuffing tube, and chemical residues of bufotenin, DMT, and harmine. That last combination is significant — harmine plus DMT is the basic pharmacology of ayahuasca. Whether the brew itself is that old, we can't quite prove. But the molecules were in the right pouch. Europe didn't go looking for psychedelics. They stumbled into them, usually while trying to convert or conquer the people who already had a relationship with these plants. The earliest written record comes from 1496, when Friar Ramon Pane — travelling with Columbus on his second voyage — described how the Taino of the Caribbean used a snuff called cohoba, made from a DMT-containing shrub. He didn't approve. He documented it anyway. Sixty-odd years later, the Spanish missionary Bernardino de Sahagún catalogued Aztec use of peyote and psilocybin mushrooms in his Florentine Codex. In the 1570s, the conquistador-physician Francisco Hernández recorded the Aztec use of ololiuqui, the seeds of a morning glory species containing LSA — a close chemical cousin to LSD. The Aztecs had their own pharmacology, fully developed, and the Spanish chroniclers preserved it, often while condemning it. It took until 1851 for ayahuasca to enter the Western written record. The English botanist Richard Spruce, exploring the upper Amazon, watched the Tukano people drink the brew and — to his credit — tried it himself. Thirteen years later, the French physician Griffon du Bellay reported iboga use in Gabon and the Congo, describing the root that would, more than a century later, become central to a particular kind of addiction recovery work. Some of the early Western encounters with psychedelics were intentional. Others were, let's say, agricultural accidents. In 1799 in London, a man went out to pick mushrooms for his family's breakfast and brought home a fistful of Psilocybe semilanceata by mistake. The whole family had what is almost certainly the first medically documented psilocybin experience in Britain. Their doctor was, by all accounts, baffled. From there, things turned more deliberate. In 1887 a Texas physician named J.R. Briggs published an account of his own peyote self-experiment. In 1893, the Comanche chief Quanah Parker handed over 50 pounds of dried peyote buttons to a Smithsonian ethnologist, and some of that material ended up in the hands of the philosopher William James. In 1897, the German pharmacologist Arthur Heffter isolated mescaline and swallowed 150 milligrams of it — the first known human experience with a purified psychedelic compound. He took careful notes, which was very on-brand for a nineteenth-century chemist. Then came 1943. Albert Hofmann, a Swiss chemist at Sandoz Laboratories, accidentally absorbed a trace of a compound he'd synthesized five years earlier and called LSD-25. A few days later, on April 19th, he ingested 250 micrograms on purpose, hopped on his bicycle to ride home, and changed the trajectory of twentieth-century neuroscience. That bike ride still gets celebrated as Bicycle Day. The man lived to 102, which is either a coincidence or a hell of an endorsement. The 1950s and early 60s were a strange, productive window. Researchers ran more than a thousand clinical studies on LSD, exploring its potential for alcoholism, depression, end-of-life anxiety, and what we'd now call PTSD. Psilocybin was synthesised by Hofmann in 1958 and quickly entered psychiatric research. For a moment it looked like Western medicine might genuinely fold these compounds into its toolkit. Then the culture turned. The compounds escaped the lab, became woven into the counterculture, and by 1970 the U.S. Controlled Substances Act had placed LSD, psilocybin, mescaline, and DMT into Schedule I — meaning, officially, no medical use and high abuse potential. Most of the world followed. Research funding evaporated. Several promising therapeutic threads simply got cut, mid-experiment. A handful of underground therapists kept working quietly. Almost everyone else moved on. This is the part of the story that's worth pausing on if you're considering plant medicine today. The reason your doctor probably can't prescribe psilocybin for your depression isn't that the science failed. It's that the science was halted, politically, for roughly forty years. We are still catching up. Somewhere around the late 1990s, the door cracked open again. Roland Griffiths' team at Johns Hopkins published carefully designed psilocybin studies showing durable reductions in depression and end-of-life distress. MAPS pushed MDMA-assisted therapy for PTSD through phase 3 trials. Imperial College London opened a dedicated Centre for Psychedelic Research. Ibogaine clinics opened in Mexico, working specifically with opioid and stimulant addiction. Ayahuasca retreats — once a rumour passed between travellers in Cusco hostels — became something a software engineer in Berlin might book on her phone. The research now points in directions that would have made Hofmann nod. Psilocybin shows real promise for treatment-resistant depression. Ibogaine appears, in observational studies, to interrupt opioid cravings in a way nothing else does. Ayahuasca has been studied for its effects on the default mode network — the brain circuitry associated with rumination and rigid self-narrative. The mechanism isn't magic. It looks more like a temporary loosening of mental ruts, with a window afterward where new patterns can take hold. That window is what serious facilitators call integration, and it's where the real work happens. A few practical things worth knowing if you're considering a retreat: Here's the honest version. The plants and compounds we now call psychedelics have been part of human life for thousands of years, used by people who took the work seriously and built elaborate frameworks around it. The West discovered them late, studied them briefly, banned them in a panic, and is now slowly, awkwardly remembering what older cultures already knew. The current renaissance isn't a discovery. It's a homecoming with paperwork. If you're considering plant medicine for addiction, trauma, or that quiet kind of depression that doesn't make a scene but rearranges your whole life — you're stepping into a tradition with deep roots, not a wellness fad. Knowing the history doesn't tell you whether a retreat is right for you. It does tell you that the question deserves more than a weekend's research. Talk to people who've done it. Read about the specific medicine you're drawn to. Find facilitators who can describe their lineage and their screening process in plain language. If something here speaks to you, the ayahuasca, psilocybin, and ibogaine retreats discussed across the broader plant-medicine world can be browsed on our marketplace here. Take your time. These plants have waited 9,000 years; they'll wait a few more weeks while you choose well.
What a Psilocybin Mushroom Trip Actually Feels Like: Inside the Experience
Picture a quiet room with a soft couch, books on the shelves, fresh flowers on a side table. It looks like somebody's living room. It isn't. It's a clinical research suite where, over the past decade, people facing terminal cancer, treatment-resistant depression, and lifelong anxiety have swallowed a capsule of psilocybin and waited for something to happen. That image — the couch, the eye shades, the careful researchers sitting nearby — has become the modern face of psychedelics. And it's a long way from the tie-dye stereotype most people still carry around. If you're reading this because you're curious about what a psilocybin journey actually feels like, or because you're weighing a psilocybin retreat for your own reasons, you deserve a clear, honest picture. Not the marketing version. The real one. One of the most consistent things people report — and one of the least talked-about in glossy write-ups — is that the experience often begins with panic. Not always. But often. A wave of anxiety swells up within thirty to sixty minutes of swallowing the capsule, and for some people it gets loud before it gets quiet. I've sat with people coming up on psilocybin in ceremonial settings, and there's a recognizable arc. The body tightens. The breath shortens. Old, half-buried thoughts surge to the surface uninvited. One participant in an early NYU study described it as physical pain that slowly revealed itself to be emotional pain — layers of grief and worry she hadn't realized she was carrying. She cried for hours. And then, eventually, the crying stopped, and something else moved in. This pattern matters because a lot of first-timers interpret the early panic as a sign they made a terrible mistake. They didn't. The discomfort is, for many, the actual work. A skilled facilitator's job in those moments isn't to make the fear stop. It's to help you stay with it long enough for it to move. Once the initial wave passes, the experience tends to widen. People describe geometric patterns blooming behind closed eyelids — gears, stars, latticework in colors that don't quite exist in waking life. Sound can take on texture. Music becomes architectural. Time bends. One young man in the same NYU trial described being carried through a series of vivid scenes: watching his own funeral in a cemetery, then dancing with his partner in Grand Central Terminal, then dropping into the sewers beneath the city, then rising to the top of the Empire State Building to watch the sun come up. None of it literal. All of it, for him, deeply meaningful. He came out of the session changed in a way he could feel but couldn't quite explain. This isn't a slideshow. It's closer to a guided lucid dream that pulls images from your own life and shows them back to you in unexpected combinations. Some people meet versions of themselves they'd forgotten. Some people sit with people they've lost. Some people feel — and this is the word that comes up over and over — connected. To other people. To the natural world. To something they don't have language for. The science is catching up to the experience, slowly. Brain-imaging studies have found that psilocybin temporarily loosens the brain's usual organizational patterns and lets regions that don't normally talk to each other start talking. The visual cortex chats with the auditory cortex — which is probably part of why people report seeing sound or hearing color. The default mode network, the part of the brain associated with rumination and self-referential thought, quiets down. Researchers at King's College London described depression as a brain stuck in a loop — the same negative thoughts circling the same well-worn tracks. Psilocybin, the theory goes, breaks the loop. For a few hours, the brain reorganizes itself. And in that window, people sometimes get a glimpse of themselves outside the loop they've been trapped in for years. Clinical work on psilocybin for end-of-life anxiety, treatment-resistant depression, and addiction has produced results striking enough that the FDA designated it a breakthrough therapy. That doesn't mean it's a cure. It means the evidence is strong enough to take seriously. Here's where the honest part comes in. Psilocybin isn't a pleasure trip, and the people who get the most out of it usually aren't chasing one. The folks I've watched benefit most are people who arrive with a specific question, a specific weight, a specific stuck place. They aren't expecting magic. They're hoping for movement. It's also not for everyone. A short list of people for whom this is genuinely risky: If you're outside those categories and you're considering a retreat for depression, addiction recovery, or simply because you've felt stuck for a long time, the next question is where to go and who to sit with. That matters more than the dose, more than the location, more than almost anything else. Reputable psilocybin retreats — legal ones operate in places like the Netherlands, Jamaica, Mexico, and parts of the U.S. where local laws have shifted — share a few things in common. Worth knowing before you book: Costs vary wildly. A solid week-long psilocybin retreat in a legal jurisdiction typically runs somewhere between two and six thousand dollars, depending on accommodation, group size, and how much wraparound care is included. Cheaper than that, and something is usually being cut. Much more than that, and you're paying for branding. One thing nobody quite prepares you for: the experience doesn't end when the substance wears off. People often describe a kind of afterglow in the first few days — softer, more open, less reactive. Then real life shows up again, and the question becomes whether you can hold on to whatever you learned when the alarm clock and the inbox come back. This is where integration earns its keep. Talking to a therapist who understands psychedelics. Journaling. Time in nature. Quiet. The insights from a psilocybin journey are fragile in the way dreams are fragile — strong while you're in them, slippery once you step back into ordinary time. Writing things down in the first 48 hours helps. So does deliberately reorganizing some small piece of your daily life around what you learned. People who treat the journey as a one-time event tend to drift back to where they were within a few months. People who treat it as the beginning of a longer conversation with themselves tend to get more out of it. The medicine opens a door. You still have to walk through it. Psilocybin isn't a shortcut. It's not a replacement for therapy, for community, for the slow work of changing a life. It can be a powerful catalyst, and for some people it's been the thing that finally cracked open a years-long depression or a pattern of addiction that nothing else could touch. For others, it's been a strange, difficult few hours that didn't deliver the breakthrough they'd hoped for. Both outcomes are real. Going in with realistic expectations — and with the right people around you — is what tips the odds toward the kind of experience worth having. If something here has stirred your curiosity and you want to look at what's actually out there, a selection of vetted psilocybin retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be there when you're ready.
Psychedelics and Grief: How Plant Medicine Helped Me Process My Father's Sudden Death
My father died in his sleep on a quiet morning in December. He was sixty. The cause, in the end, was the bottle — a long, slow story with a short, brutal final chapter. Grief like that doesn't arrive in a single wave. It seeps in. It sits in your chest for weeks before you notice it's been there the whole time, breathing in and out with you. What I want to write about isn't really about the death. It's about what came after — specifically, the role that psychedelics played in helping my brother and me actually feel the loss instead of armouring against it. Plant medicine and grief is a quiet conversation happening in living rooms and rented cabins all over the world right now, and I think it deserves to be talked about honestly, without either the breathless evangelism or the reflexive sneer. What follows is one story. Mine. It's not a clinical recommendation. But if you're researching whether psychedelic healing might have a place in your own life — for grief, for addiction recovery, for the patterns you can't quite shake — maybe some of it will be useful. A few days after the funeral, my brother Rory and I rented a small cabin in the southern English countryside. Neither of us could stand being in the house where it had happened. We needed walls that didn't remember anything. Rory had brought a small bag of Hawaiian baby woodrose seeds — the source of LSA, a naturally occurring psychedelic that's a chemical cousin of LSD. He'd picked them up legally in Amsterdam months earlier, with no particular plan. When he suggested we take them together, I thought about it for maybe ten seconds. It seemed, frankly, a healthier option than what we were both quietly drifting toward, which was drinking ourselves into the same grave our dad had dug. An hour in, the room softened. Two hours in, we were hugging — really hugging, not the British half-pat that passes for affection in our family. We told each other things we'd never said. We cried. We laughed at how absurd it was that two grown men needed a handful of seeds to finally say the obvious. By morning the first snow of the winter was falling outside the cabin window, and something between us had shifted in a way that has held ever since. I'm not going to pretend my anecdote is evidence. It isn't. But there's a reason the conversation around psychedelics, addiction, and trauma has gone from fringe to front-page in the last few years — and grief sits squarely inside that conversation. Researchers studying psilocybin and 5-MeO-DMT think these compounds temporarily loosen the brain's habitual patterns. Grief, like depression and like addiction, tends to lock the mind into well-worn grooves: the same thoughts, the same avoidances, the same numbing strategies. A psychedelic experience can briefly disrupt those grooves — long enough for something new to land. A study launched at the University of Texas' Dell Medical School in late 2022 set out to test exactly this in widows of veterans, comparing psilocybin and 5-MeO-DMT against no treatment. The researchers there have spoken openly about the theory: that these molecules can interrupt depressive patterns and let the brain run differently for a while. Whether that translates into durable relief from prolonged grief is still being worked out. The early signals are interesting. They are not yet proof. Six months after Dad died, I travelled to a retreat in Mexico to observe — and to work with — 5-MeO-DMT. People call it the God Molecule. They also call it the toad, because the version most commonly used is derived from the venom of the Sonoran Desert toad. It's the fastest-acting and arguably the most overwhelming of the classic psychedelics. A full dose lasts maybe twenty minutes. It feels like a lifetime. By the time I sat down on the mat, Dad wasn't at the front of my mind. Life had moved on, the way life does. But when the medicine hit, every unresolved scrap I was still carrying — his drinking, his absence, the moments I was angry with him, the moments I missed him — surfaced at once. I wept in a way I hadn't allowed myself to weep at any point during the months prior. And then, somehow, on the other side of the weeping, there was something I can only describe as a wave of release. A surrender. A blissful, full-body letting go. I've thought about that twenty minutes many times since. What it gave me wasn't a memory or an insight. It was a kind of permission. Permission to stop bracing. The plant-medicine traditions of the Amazon talk about ayahuasca, San Pedro, tobacco, and others as master plants — teachers, not just substances. Whether or not you buy the spiritual framing, there's something useful in it: these medicines tend to work by softening the ego's defences and letting feeling move through you that was previously stuck. That softening is, I think, what made the night in the cabin with my brother so important. We didn't have a shaman. We didn't have a ceremony. We had each other and a willingness to drop our guard. The medicine did the rest. And the bond it formed has outlasted the trip by years. Some of the most credible work emerging right now on psychedelics for addiction recovery points at exactly this mechanism. Whether the substance is ayahuasca, psilocybin, ibogaine, or 5-MeO-DMT, the consistent thread in the participant reports isn't a chemical fix. It's a re-opening — to oneself, to other people, to grief that had been buried, to love that had been blocked off. I'm wary of telling anyone what to do here. Psychedelics aren't a universal answer and they aren't risk-free. People with certain heart conditions, certain medications, and certain mental-health histories should not take them. A reputable retreat will screen for all of that before they take your booking. If a retreat doesn't ask hard medical and psychological questions before accepting you, that itself is a red flag. A few things worth thinking about if you're researching: Cost varies wildly. A short psilocybin retreat in the Netherlands might run a thousand euros; a two-week ibogaine programme for addiction recovery in Mexico can stretch past ten thousand dollars. Ayahuasca retreats in Peru sit somewhere in between, depending on length and lineage. Cheap usually means corners cut. Expensive doesn't automatically mean good. If there's one thing my brother and I figured out, it's that grief doesn't want to be solved. It wants to be felt. The reason psychedelics seem to help — for some people, sometimes — isn't that they erase the pain. They make the pain accessible. They lower the walls long enough for you to walk in and meet what's there. That's why the integration piece matters so much. The medicine opens the door. You still have to walk through it, day after day, in the months that follow. Therapy helps. Honest friendships help. Time helps. Writing it down helps. The trip is a beginning, never an end. I miss my dad. I always will. But the grief that used to sit on my chest like a stone now sits more like a friend who visits sometimes — sad, familiar, no longer crushing. I credit a lot of things for that shift. The medicines are among them. So is my brother. So is time. If something in this piece has landed, and you want to look more closely at what's out there, a range of curated ayahuasca, psilocybin, and 5-MeO-DMT retreats can be browsed on our marketplace here. Take your time with the decision. The right retreat will still be there next month.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
